See more : Oceaneering International, Inc. (0KAN.L) Income Statement Analysis – Financial Results
Complete financial analysis of UTime Limited (WTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of UTime Limited, a leading company in the Consumer Electronics industry within the Technology sector.
- Flexium Interconnect, Inc. (6269.TW) Income Statement Analysis – Financial Results
- EKF Diagnostics Holdings plc (EKDHF) Income Statement Analysis – Financial Results
- Woodside Energy Group Ltd (WDS.AX) Income Statement Analysis – Financial Results
- Workforce Holdings Limited (WKF.JO) Income Statement Analysis – Financial Results
- Helix BioPharma Corp. (HBP.TO) Income Statement Analysis – Financial Results
UTime Limited (WTO)
About UTime Limited
UTime Limited, together with its subsidiaries, designs, develops, manufactures, sells, and operates mobile phones, accessories, and related consumer electronics. The company offers consumer electronics, such as power banks, bluetooth speakers, batteries, chargers, cell phone parts, molds, and shells. It provides electronics manufacturing services, including original equipment manufacturer and original design manufacturer services. It sells its products under the UTime and Do brand names in South America, South Asia, Southeast Asia, and Africa. UTime Limited was founded in 2008 and is headquartered in Shenzhen, China.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 172.16M | 200.55M | 275.51M | 246.90M | 193.09M | 35.48M | 60.08M | 107.15M |
Cost of Revenue | 163.29M | 170.48M | 261.72M | 228.73M | 173.74M | 31.75M | 55.45M | 99.18M |
Gross Profit | 8.87M | 30.07M | 13.79M | 18.17M | 19.35M | 3.72M | 4.63M | 7.97M |
Gross Profit Ratio | 5.15% | 14.99% | 5.00% | 7.36% | 10.02% | 10.50% | 7.70% | 7.44% |
Research & Development | 16.65M | 2.33M | 2.22M | 1.10M | 1.52M | 1.57M | 2.31M | 3.08M |
General & Administrative | 40.71M | 110.41M | 39.50M | 25.70M | 29.55M | 4.09M | 4.64M | 4.90M |
Selling & Marketing | 6.36M | 7.39M | 5.46M | 4.13M | 9.51M | 2.15M | 2.59M | 2.15M |
SG&A | 47.07M | 117.80M | 44.96M | 29.82M | 39.06M | 6.24M | 7.23M | 7.04M |
Other Expenses | -24.70M | -79.00K | -109.00K | -464.00K | 4.00K | 0.00 | 0.00 | 0.00 |
Operating Expenses | 39.01M | 117.21M | 45.51M | 27.70M | 38.72M | 5.21M | 9.49M | 6.59M |
Cost & Expenses | 202.30M | 287.69M | 307.24M | 256.43M | 212.46M | 36.96M | 64.94M | 105.77M |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 220.36K | 124.18K | 150.89K |
Interest Expense | 3.62M | 6.15M | 4.88M | 2.46M | 1.75M | 1.48M | 779.00K | 1.04M |
Depreciation & Amortization | 6.74M | 5.79M | 4.33M | 3.95M | 4.03M | 475.60K | 251.54K | 230.62K |
EBITDA | -23.40M | -71.84M | -30.17M | -10.58M | -15.68M | -6.78M | -20.98M | 1.23M |
EBITDA Ratio | -13.59% | -40.60% | -9.98% | -2.78% | -7.95% | -4.70% | -5.57% | 1.14% |
Operating Income | -30.14M | -84.04M | -34.50M | -14.53M | -19.71M | -2.14M | -3.60M | 994.93K |
Operating Income Ratio | -17.51% | -41.91% | -12.52% | -5.88% | -10.21% | -6.04% | -5.98% | 0.93% |
Total Other Income/Expenses | -3.62M | -6.15M | -4.88M | -2.46M | -1.75M | -1.48M | -779.00K | 235.84K |
Income Before Tax | -33.76M | -90.19M | -39.38M | -16.99M | -21.45M | -1.71M | -4.99M | 1.23M |
Income Before Tax Ratio | -19.61% | -44.97% | -14.29% | -6.88% | -11.11% | -4.81% | -8.30% | 1.15% |
Income Tax Expense | -171.00K | -171.00K | -46.00K | -364.00K | 247.00K | 74.20K | 16.90K | 282.61K |
Net Income | -60.88M | -87.62M | -38.83M | -16.63M | -21.70M | -1.62M | -2.89M | 485.63K |
Net Income Ratio | -35.37% | -43.69% | -14.10% | -6.73% | -11.24% | -4.58% | -4.81% | 0.45% |
EPS | -48.73 | -7.80 | -4.76 | -3.68 | -4.81 | -0.37 | -0.42 | 0.07 |
EPS Diluted | -91.97 | -7.80 | -4.76 | -3.68 | -4.81 | -0.37 | -0.42 | 0.07 |
Weighted Avg Shares Out | 1.25M | 11.23M | 8.16M | 4.52M | 4.51M | 4.38M | 6.90M | 6.90M |
Weighted Avg Shares Out (Dil) | 662.03K | 11.23M | 8.16M | 4.52M | 4.51M | 4.38M | 6.90M | 6.90M |
EU tariffs on Chinese electric cars based on WTO rules, Renault boss says
UTime Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency
UTime Limited Announces Pricing of $5 Million Registered Direct Offering
Spain's Sánchez urges negotiated solution to China-EU trade tensions
UTime Limited Announces 1-For-25 Reverse Share Split
Remarkable Announcement on Significant Fluctuation of the UTime's Share Price
UTime Initiates Financial and Legal Due Diligence on Bowen Therapeutics
UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines
About Circul VS: A Core Continuous Blood Pressure Measurement Technology System Developed in Partnership with Dr. Ehud Baron
UTime Limited to Participate in International Medical Fairs and Medical Conferences
Source: https://incomestatements.info
Category: Stock Reports